Pulmonary hypertension after hematopoietic stem cell transplantation

Biol Blood Marrow Transplant. 2013 Nov;19(11):1546-56. doi: 10.1016/j.bbmt.2013.07.017. Epub 2013 Jul 23.


Pulmonary hypertension (PH) is a potentially fatal complication of hematopoietic stem cell transplantation (HSCT). Given its nonspecific clinical presentation, it is likely that this clinical entity is underdiagnosed after HSCT. Data describing the incidence, risk factors, and etiology of PH in HSCT recipients are minimal. Physicians caring for HSCT recipients should be aware of this severe post-transplant complication because timely diagnosis and treatment may allow improved clinical outcomes. We summarize the pathophysiology, clinical presentation, diagnosis, and management of PH in HSCT recipients.

Keywords: Pulmonary arterial hypertension; Pulmonary hypertension; Pulmonary veno-occlusive disease; Thrombotic microangiopathy.

Publication types

  • Review

MeSH terms

  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Hypertension, Pulmonary / etiology*
  • Risk Factors
  • Transplantation Conditioning / adverse effects
  • Transplantation, Autologous